flowchart LR
A["Vaccination Administered"] --> B["Adverse Event Identification"]
B --> C["Site Documentation & Reporting"]
C --> D["Safety Database Entry"]
D --> E["Aggregate Safety Review"]
E --> F{"Safety Signal Identified?"}
F -- "No" --> G["Continue Routine Surveillance"]
G --> A
F -- "Yes" --> H["Safety Escalation"]
H --> I["Cross-Functional Review\n(Safety, Clinical, PM)"]
I --> J["Governance Decision"]
J --> K["Protocol Clarification / Training /\nMonitoring Adjustment"]
K --> A
76 Vaccine Trials Quick Reference
Because vaccine trials commonly enroll healthy participants, unexpected safety events may receive heightened regulatory attention even when event severity is low.
76.1 Vaccine Accountability Flow
Vaccine accountability is a critical operational component of vaccine clinical trials due to the need to ensure traceability of administered doses and proper handling of temperature-sensitive investigational product.
The accountability process typically includes:
- Receipt and verification of vaccine shipment
- Storage under protocol-defined temperature conditions
- Documentation of temperature monitoring
- Dose preparation and administration
- Documentation of subject-level accountability
- Reconciliation of used and unused doses
Monitoring activities frequently focus on:
- consistency between accountability logs and administered doses,
- temperature excursion documentation,
- completeness of dispensing records,
- and reconciliation accuracy.
Because vaccine products are often administered to large populations, accountability discrepancies may have amplified regulatory significance.
76.2 Safety Signal Review Cadence
Vaccine trials frequently implement structured safety signal review processes due to the enrollment of healthy populations and heightened regulatory sensitivity to emerging safety trends.
Safety review may occur at defined intervals and typically includes:
- aggregate adverse event review,
- comparison of event rates across sites,
- evaluation of unexpected event patterns,
- review of medically attended events,
- and assessment of temporal relationships to vaccination.
Operational implications include:
- rapid escalation pathways for emerging safety signals,
- cross-functional review involving safety, clinical, and project management,
- and documentation of governance decisions related to safety oversight.
In accelerated or large-scale vaccine trials, safety review cadence may increase during periods of rapid enrollment.
76.3 Vaccine Safety Signal Review Workflow
CRAs should verify that adverse events are documented and reported consistently, even when events are expected or non-serious. In vaccine trials involving healthy participants, incomplete AE documentation may receive heightened regulatory scrutiny.